Planning a life sciences manufacturing facility as a distinct real estate and operational asset — separate from laboratory and research space — is one of the most consequential decisions a growing biotech or pharmaceutical organization can make. The two functions look similar on the surface: both require controlled environments, specialized infrastructure, and proximity to skilled talent. But they diverge sharply in regulatory classification, building specification, zoning requirements, and long-term capital exposure, and conflating them in a single facility strategy is a reliable way to slow a development pipeline or trigger costly retrofits later.
Establishing a Clear Regulatory Classification Before Any Site Work
The first technical step in answering how to plan a life sciences manufacturing facility separate from research space is to establish the product's regulatory classification and the manufacturing classification that follows from it. For pharmaceutical manufacturing in the United States, the relevant framework is current Good Manufacturing Practice, enforced by the Food and Drug Administration. Biologics, small molecules, cell and gene therapies, and combination products each carry different facility expectations, and the classification determines cleanroom requirements, contained manufacturing provisions, and utilities standards.
Regulatory classification also determines which building codes and local ordinances apply. A facility manufacturing a Schedule I or II controlled substance will face Drug Enforcement Administration registration and physical security requirements that have no analog in a research setting. A cell therapy manufacturer producing an Advanced Therapy Medicinal Product for European distribution must simultaneously satisfy FDA expectations and those of the European Medicines Agency.
Establishing classification before site selection matters because zoning, permitting timelines, and neighboring-use restrictions vary dramatically based on what a facility will manufacture. Some jurisdictions prohibit high-potency compound manufacturing in corridors otherwise friendly to biotech campuses. Learning that after executing a letter of intent is an expensive lesson.
The regulatory classification also anchors the facility programming document, which is the internal brief that specifies room counts, cleanroom grades, utilities, and adjacencies. Without a confirmed classification, the program is a guess, and a guess built into a lease or a construction contract becomes a liability.
Writing the Facility Programming Document
The programming document is the bridge between regulatory requirements and real estate criteria. For a manufacturing facility, it must specify cleanroom classifications using the ISO 14644 framework or equivalent local standard, identify whether aseptic processing areas are required, define the environmental monitoring zones, and calculate the mechanical space required to support each production area.
Utilities must be called out in the program with the same specificity as production rooms. Purified water and water-for-injection systems, clean steam, compressed gases, nitrogen blanketing, and emergency power all have space implications. Each system requires dedicated equipment rooms, pipe chases, and maintenance access corridors, and those secondary spaces can equal or exceed the footprint of the primary production rooms they serve.
The document should also specify personnel and material flow logic. Regulatory guidance for sterile manufacturing, for example, requires that personnel and product pathways never cross contamination boundaries without passing through appropriate airlocks, gowning rooms, or decontamination interlocks. Mapping these flows in the program document before a building is selected prevents the common error of choosing a building whose column grid or structural depth cannot accommodate the required circulation layout.
A well-written program document is also a facility-planning instrument for the real estate search. It converts regulatory and operational requirements into measurable building specifications: clear height minimums, floor-load ratings, electrical capacity in megavolt-amperes, and minimum mechanical penthouse or mezzanine allocation. Those specifications become the screening criteria for candidate buildings and sites.
Site Selection Criteria for Manufacturing Versus Research Space
Research tenants in the life sciences tend to cluster in established innovation corridors because proximity to academic medical centers, talent pipelines, and peer institutions drives scientific productivity. Manufacturing tenants face a different optimization problem. Talent is still a constraint, but the workforce profile shifts from PhD scientists to GMP-trained operators, quality technicians, and regulatory affairs professionals — a pool that is often distributed differently across a metropolitan area.
Zoning is the most immediate site filter. Life sciences manufacturing typically falls under a heavy industrial or specialized pharmaceutical manufacturing designation, and not every municipality that welcomes biotech research zoning will permit the emissions, wastewater, or traffic profiles associated with a commercial-scale manufacturing facility. Confirming zoning compatibility and reviewing the jurisdiction's conditional-use permit process should precede any site financial analysis.
Utilities infrastructure deserves equal weight. A cell therapy manufacturer or a large-scale bioreactor operation can draw electrical loads an order of magnitude larger than a comparably sized research building. Confirming that a substation with adequate transformer capacity exists on or adjacent to the site — and understanding the utility's lead time to upgrade service — is essential before a facility-planning process advances past the screening phase.
Transportation infrastructure affects both supply chain and regulatory compliance. Raw material and component deliveries, finished goods distribution, and waste removal all require appropriate truck access, dock configurations, and potentially rail or highway proximity for large-scale operations. For products requiring cold-chain logistics, proximity to a qualified third-party logistics provider or a major air cargo hub may be a hard constraint.
Evaluating Building Specifications Against Manufacturing Requirements
Once candidate sites are identified, the evaluation shifts to building-level specification analysis. Existing structures can accelerate timelines and reduce capital expenditure relative to ground-up development, but they must meet a threshold of adaptability that varies significantly by manufacturing type.
Floor-to-floor height is the starting point. A sterile fill-finish operation requires HVAC air-handling units, fan filter units, and ductwork infrastructure above the cleanroom ceiling — often adding four to six meters of mechanical depth above a cleanroom rated to ISO 5. A building with ten-meter floor-to-floor clearance may accommodate that stack; a building designed for general office or light assembly will not, regardless of how attractive the lease economics appear.
Structural floor loading is the second filter. Manufacturing equipment — centrifuges, bioreactors, freeze dryers, autoclave units, and large-format packaging lines — imposes point loads and distributed loads that exceed typical commercial construction standards. A structural engineer must assess whether the slab-on-grade or elevated deck can support the process equipment loads specified in the programming document, and the cost of remediation must be incorporated into the financial model before shortlisting.
The electrical infrastructure assessment must address not only the available service but also the facility's ability to maintain power quality and continuity. Cleanroom HVAC, environmental monitoring systems, and certain laboratory instruments are sensitive to voltage fluctuations. An uninterruptible power supply and a standby generator sized to maintain critical systems through a utility interruption are baseline requirements, and the building's electrical room must have physical space to accommodate that equipment.
Water and waste infrastructure rounds out the building assessment. Pharmaceutical manufacturing generates process effluent streams that may require pre-treatment before discharge to municipal sewers. The permitting for an industrial pretreatment facility takes time, and a site without adequate sewer capacity or with a municipality that lacks a pretreatment program may be disqualified regardless of other positive attributes.
Financial Modeling for a Standalone Manufacturing Asset
A manufacturing facility carries a fundamentally different financial profile than research or office space, and the economic model must reflect that difference from the first analysis. Tenant improvement allowances in research markets have expanded considerably in established life sciences corridors, but manufacturing tenants often find that landlords are less willing to fund specialized infrastructure because the residual value of GMP-fitted space is narrower than wet lab build-out.
The effective rent comparison must account for total occupancy cost, not headline rent alone. A building offered at a lower base rent but requiring significant tenant-funded capital for electrical upgrades, dock construction, or mechanical space creation may carry a higher ten-year net present value of occupancy cost than a higher-rent building that is closer to specification. Calculating lease net present value using a risk-adjusted discount rate that reflects capital timing and project-specific uncertainty is the appropriate method for making that comparison.
Build-to-suit arrangements introduce a different financial logic. A developer who constructs a facility to a tenant's specification will typically embed the construction cost in the rent structure over a long initial term, often fifteen to twenty years, with limited flexibility to exit without substantial penalty. The tenant receives a purpose-built asset without upfront capital outlay, but the organization accepts long-duration real estate obligation tied to a product whose commercial trajectory may change. Scenario analysis across multiple demand assumptions is essential before committing to a build-to-suit structure.
Sale-leaseback transactions offer a hybrid path for organizations that have already built or acquired a manufacturing asset and wish to redeploy the balance sheet. In a sale-leaseback, the organization sells the building to an investor and simultaneously enters a long-term lease, freeing capital for clinical programs or commercial infrastructure. The analysis requires modeling the after-tax proceeds, the present value of the lease obligation, and the opportunity cost of the capital unlocked — a calculation that sits at the intersection of real estate finance and corporate treasury strategy.
Managing Regulatory and Environmental Permitting Timelines
Manufacturing facilities operate in a permitting environment that is several orders of complexity above research tenancies, and timeline risk is the most common source of project delay. The regulatory pathway involves at least three distinct permitting tracks that can run in parallel but must all converge before operations begin.
Building permit approval for a GMP facility often requires pre-application meetings with the authority having jurisdiction, submission of specialized documentation for cleanroom systems, and third-party review of fire suppression and life safety designs. In jurisdictions with limited experience reviewing pharmaceutical manufacturing applications, this process can extend significantly beyond standard commercial construction timelines.
Air quality permitting applies when manufacturing processes generate volatile organic compounds, particulate emissions, or other regulated air pollutants. The permit application must characterize emissions from each process step, model the impact on surrounding air quality, and in some cases propose best available control technology. The timeline for a minor source permit is typically measured in months; a major source application can take considerably longer and may require public comment periods.
Wastewater pretreatment permits, DEA registration for controlled substances, and state-level pharmaceutical manufacturing licenses each add parallel permitting workstreams. Building a Gantt chart that maps every permit application, its dependencies, and its worst-case timeline is a foundational project management tool. The critical path is almost always a permitting milestone, not a construction milestone, in complex GMP facility projects.
The practical advice for teams managing this complexity is to engage regulatory affairs consultants and environmental permitting specialists during site selection — not after a site is selected. Many jurisdictions will provide pre-application guidance, and that guidance can reveal fatal flaws or unexpected accelerators before significant capital is committed.
Separating the Research and Manufacturing Operational Models
Even when a life sciences organization co-locates manufacturing and research functions within a single campus or master plan, the two facilities must operate under completely separate quality management systems, organizational hierarchies, and physical access controls. Research staff do not have unrestricted access to manufacturing suites, and manufacturing staff are not expected to follow research protocols.
The separation is regulatory as well as operational. A manufacturing site's Master Production Records, batch records, environmental monitoring programs, and change control procedures are all GMP-controlled documents. Introducing research-stage materials or procedures into a manufacturing environment without formal change control is a compliance event that can result in an observation on an FDA Form 483 or, in serious cases, a Warning Letter.
Physical separation — meaning walls, airlocks, and access control systems that prevent inadvertent co-mingling of personnel and materials — is the most defensible implementation of this principle. Electronic access systems tied to role-based permissions, combined with gowning and hygiene protocols specific to each space classification, provide the audit trail that regulatory inspectors expect to find.
Organizationally, the separation is maintained through distinct reporting lines for the head of manufacturing and the head of research, each with independent quality oversight. Many organizations establish a site quality director who reports outside the operational hierarchy to prevent manufacturing pressure from overriding quality decisions — a structure that the FDA's quality oversight expectations effectively require for licensed manufacturing sites.
Structuring the Facility Planning Team and Governance
A manufacturing facility planning process involves a wider stakeholder group than any typical commercial real estate transaction, and governance structure determines whether that complexity produces good decisions or costly delays. The core team typically includes a real estate lead, a regulatory affairs representative, a process engineering lead, a quality assurance representative, and a finance or treasury stakeholder who owns the capital allocation model.
Each stakeholder brings a veto-equivalent constraint. Real estate owns site feasibility. Regulatory affairs owns classification and permitting viability. Process engineering owns the manufacturing program. Quality owns GMP compliance. Finance owns the investment thesis and the return hurdle. A governance structure that requires documented sign-off from each function at each stage gate prevents the common failure mode where a site advances to LOI negotiation before quality or regulatory has reviewed the building specifications.
Stage gates for a manufacturing facility project typically include program confirmation, site long-list development, site short-list evaluation, preferred site selection, and financial commitment. The first three gates are almost entirely analytical; the last two require executive alignment. Building in a formal review meeting at each gate, with written output from each stakeholder function, creates accountability and a decision audit trail that is useful if the project is later reviewed by a board, an investor, or a regulatory agency.
Third-party advisers — including life sciences real estate specialists, GMP design engineers, environmental consultants, and legal counsel familiar with pharmaceutical regulation — should be engaged before the site search begins, not after. The cost of expert advice in the planning phase is small relative to the cost of correcting errors discovered during construction or regulatory review.
Using Technology and Platforms in the Facility Planning Process
The complexity of a manufacturing facility search generates a large volume of property data, regulatory research, financial analyses, and stakeholder communications that must be organized and accessible throughout a project that may span eighteen to thirty-six months.
Coordinating Construction, Commissioning, and Qualification
Once a site is selected and permits are secured, the manufacturing facility planning process transitions into construction oversight and the regulated qualification process. For GMP facilities, construction is not complete when the contractor achieves substantial completion — it is complete when the facility has been commissioned, qualified, and validated to the standard that supports a regulatory filing.
Commissioning verifies that installed systems operate as designed. Qualification demonstrates, through documented testing, that the systems perform within specified parameters under actual operating conditions. For sterile manufacturing, the qualification program includes installation qualification, operational qualification, and performance qualification for each critical system, followed by a media fill program that simulates aseptic processing with microbiological growth media in place of the drug product.
The timeline from construction completion to first regulatory submission is frequently underestimated. Organizations that begin writing qualification protocols only after construction is complete will be disappointed. Protocol development, review, and approval within the quality management system must begin during the design phase, so that testing can begin immediately when systems are handed over by the contractor.
Engaging a contract manufacturing organization for interim supply while a proprietary facility is being qualified is a common hedge against timeline risk. The economics of this arrangement — paying a CMO's commercial margin versus carrying the fixed cost of an underutilized internal facility — should be modeled explicitly and updated as construction milestones become clearer.
Integrating Portfolio Strategy With Long-Term Manufacturing Footprint
A manufacturing facility represents a long-duration real estate commitment, and the organization's portfolio strategy must account for how that commitment interacts with the rest of the real estate footprint. Research space can be rationalized or expanded relatively quickly as programs advance or fail; manufacturing capacity is slower to add and more expensive to exit.
Portfolio scenario planning for a life sciences organization with a manufacturing facility should model at least three futures: a base case where the product advances on schedule, a downside case where development timelines extend and manufacturing ramp is delayed, and an upside case where commercial demand exceeds the facility's initial capacity design. Each scenario implies different sublease exposure, expansion option value, and capital timing, and those implications must be carried forward into the annual real estate plan.
Critical dates management is a discipline that becomes essential when a manufacturing lease or build-to-suit includes expansion options, termination rights, or rent review provisions with specific notice periods. Missing an option exercise window in a manufacturing context can mean accepting a lease renewal on landlord terms or losing a right to expand into adjacent space that took years to negotiate.
The integration of facility planning into broader portfolio strategy also involves the organization's treasury and investor relations functions when the manufacturing asset is material to the balance sheet. A large build-to-suit or owned manufacturing facility may appear on the balance sheet under lease accounting standards that require the organization to recognize a right-of-use asset and a corresponding lease liability, with implications for leverage ratios and covenant compliance that should be reviewed with legal and financial counsel before the lease is executed.
About Advantai
Advantai is a commercial real estate intelligence and operations platform. It connects client relationships, property research, documents, and financial decisions in one workspace for commercial real estate teams — advisers and brokerage teams, occupier and facility teams, and portfolio teams. The platform covers CRM and origination, requirements and site selection, Property X-Ray (an interactive 3D building workspace), financial modeling and comparison, document intelligence, transactions and diligence, client collaboration, and portfolio strategy with critical dates. The optional Super Agent upgrade adds specialist, source-backed research and automated scenario analysis.
Get Started with Advantai
Ready to see your next move clearly? Go to advantaico.com, click Request a demo and tell us about your next project. Prefer to start with a single project? Visit advantaico.com/getting-started to plan your first one.